Navigation Links
Dr. Oz, Host Of The Dr. Oz Show, and Harry Zhabilov Of Immunotech Laboratories Discuss Immunotherapy Treatments For Cancer, HIV/AIDS

HUNTINGTON BEACH, Calif., Feb. 6, 2013 /PRNewswire/ -- Recently was able to ask Dr. Mehmet Oz , host of the Dr. Oz show and Harry Zhabilov, President of Immunotech Laboratories (PINKSHEETS:IMMB) about Immunotherapy Treatments and how they are used to treat patients suffering with Cancer, and HIV/AIDS Virus.

Dr. Oz demonstrates an amazing wealth of knowledge in Immunotherapy.  The Doctor is not only charismatic, but also articulates his incredible knowledge about the treatment thoroughly.  Dr. Otis Brawley from the American Cancer Society also added some unique advancement comments about Immunotherapy Treatments.

Please view the video featuring Harry Zhabilov, Dr. Oz, and Dr. Otis Brawley at the following YouTube link.

Review video testimonials of now symptom free Cancer and HIV patients treated with Immunotech's IPF Technology at

About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases suck as HIV, Cancer, Hepatitis and Aids. Immunotech is committed to creating drugs for the better health of mankind.

About Undiscovered Companies
Undiscovered Companies is a video news provider of public and private companies looking for new marketing ideas and product exposure.  Subscribe at for free.

Safe Harbor Statement: This release may include the use of forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit our website, for complete risks and disclosures.

Immunotech Laboratories

Undiscovered Companies

SOURCE Immunotech Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
2. Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
3. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
4. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
5. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
6. Heraeus Named "Supplier of the Year" by National Association of Dental Laboratories
7. New Jensen Dental White Paper Reveals How Dental Laboratories Can Increase Productivity, Profitability with a Multi-Function Pressing Furnace
8. AAIPharma Announces Promotion Of Dean Shirazi To EVP Of Analytical Laboratories
9. IDEXX Laboratories Announces Entry Into Consent Agreement with FTC Bureau of Competition Staff
10. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
11. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
Post Your Comments:
(Date:12/1/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel ... the company will present at the LD Micro Main Event. ... Sunset Boulevard Hotel in Los Angeles, CA. ... present on Thursday, December 3, at 9:00 am Pacific time ... at least 10 minutes prior to the start of the ...
(Date:12/1/2015)... Dec. 1, 2015   MabVax Therapeutics Holdings, Inc ... announces it has filed an Investigational New Drug Application ... for the Company,s lead fully human antibody product HuMab ... MabVax plans to initiate the Phase I clinical trial ... --> The planned Phase I trial will ...
(Date:12/1/2015)... 2015   Craneware, Inc ., the healthcare ... announced the company will showcase a new version ... solution at the American Society for Health-System ... The new features are focused on simplifying and ... managing enterprise-wide pharmacy charges to ensure compliance and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... Speech and physical therapies are traditionally conducted ... and under the right circumstances, these practices can be merged. This combination ... his or her therapeutic sessions, as well as gives the physical and speech ...
(Date:12/1/2015)... Wayland, MA (PRWEB) , ... December 01, 2015 , ... ... adults has a tattoo — a number even greater among Millennials (a whopping one ... there are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... Libertyville, IL (PRWEB) , ... December 01, 2015 ... ... catheters, keeping their independence is everything. That is why Hollister Incorporated has launched ... excited to offer this next product in the VaPro touch free catheter portfolio,” ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of ... latest addition to the devices for sale in the United States. Clarity is ... long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to own ...
(Date:12/1/2015)... , ... December 01, 2015 , ... With FCPX ... and with full control over customization, the possibilities are truly endless, all with a ... randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, all ...
Breaking Medicine News(10 mins):